Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans

STELLAR to begin enrolling pediatric subjects STARPATH prescreening study open for adults and children with Stargardt disease to streamline entry into future ACDN-01 clinical trials BOSTON, May 4, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human...